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T he orbit in Graves disease (GD) exhibits remarkable reactivity (1) . In the most severe cases, thyroidassociated ophthalmopathy (TAO) can distort tissue architecture, cause dysfunction, and impair vision. Much of the functional disruption associated with TAO results from end-stage fibrosis. Typically, the course of TAO can be parsed into two clinically recognizable phases, as described by Rundle and Wilson (2) . Initially, it presents as a constellation of signs and symptoms attributable to inflammation and localized edema that can extend beyond the anatomic boundaries of the orbit to the upper face. This active phase usually lasts from 1 to 3 years. It gives way to the chronic/stable phase in which the disease ceases changing and when processes, such as fat expansion, muscle enlargement, and fibrosis, are thought to be irreversible. Underlying this characteristic pattern of tissue remodeling appear to be orbital fibroblasts (OFs), which are cells possessing unusual phenotypic attributes. The nature and derivation of OFs have long been speculated about but their precise lineage has remained uncertain. They are generally considered to be neural crest in origin (3) . Besides residential OFs, fibroblasts within the orbit could also result from epithelial-mesenchymal transitions (4) or represent cells infiltrating from other anatomic regions, most notably the bone marrow (5, 6) .
OFs derived from orbital tissues manifesting TAO exhibit particular cellular heterogeneity and exaggerated responses to many molecular factors in vitro. They hereafter are referred to as GD-OFs. Their unusual characteristics were initially recognized nearly 50 years ago when Sisson et al. (7) began cultivating OFs in vitro. These investigators determined that the release of glycosaminoglycans and glucose utilization in GD-OFs were enhanced when cocultured with lymphocytes (8) . These findings remained largely unembellished for nearly two decades before Bahn et al. (9) proposed that cultured GD-OFs might be exploited as a model for studying TAO. Around this same time, Hiromatsu et al. (10) were cultivating OFs and comparing their susceptibility to antibody-dependent cell-mediated cytotoxicity with that of muscle cells. Weetman et al. (11) conducted immunohistochemical analysis of TAO orbital tissues and concluded that the interstitial cells were the likely immune targets in the disease. A number of studies have been performed subsequently examining the ultrastructure of GD-OFs (12, 13) , their morphologies (14) , and their biochemical attributes (15) . Furthermore, it has become clear that GD-OFs derived from orbital fat diverge from those associated with extraocular muscles (14, 16) . Of note, GD-OFs express the functional TSH receptor (TSHR) (17, 18) . Levels of this receptor are very low compared with those found on thyroid epithelial cells but can be enhanced with their differentiation into adipocytes (19) .
Many Aspects of Tissue Remodeling in TAO Can Be Directly Linked to the Phenotypes of GD-OFs
One of the dominant characteristics of fibroblasts in general and GD-OFs in particular concerns their capacity to generate substantial amounts of glycosaminoglycans (20) . A cardinal feature of TAO is the disordered accumulation of these macromolecules in the orbit and upper face (20, 21) . This material is largely hyaluronan (HA), the most abundant, nonsulfated glycosaminoglycan and one that lacks a core protein (22) . HA associates with cellular receptors, CD44 (23) and the receptor for HA-mediated motility (24, 25) , and through these interactions initiates cellular responses. It plays a key role in the orbital tissue remodeling and expansion occurring in TAO (26) . This can be attributed to its impact on vascular permeability, water content, and the chemoattractant properties of its fragments (27) . Its rheological properties include an enormous capacity for water binding. Chain length is an important determinant of the biological impact that HA exerts within tissues (28). Short-chain HA can elicit responses in a wide range of target cell types (29, 30) .
Among the early, pivotal insights into the mechanisms underlying HA generation was the subcellular localization of its synthesis to the plasma membrane (31) . Subsequently, three mammalian HA synthase (HAS) isoenzymes were identified and cloned (32, 33) . The gene encoding uridine 5 0 -diphosphate (UDP) glucose dehydrogenase was also cloned (34) . This enzyme catalyzes the oxidation of UDP glucose to UDP glucuronic acid upstream from the HAS proteins (34) . Gene promoters for these enzymes have been cloned (35, 36) . HA is produced in the orbit primarily by GD-OFs (20) , cells that express all three HAS isoenzymes. HAS2 is the most abundant and appears to dominate HA synthesis in these cells (37) . UDP glucose dehydrogenase is also expressed by GD-OFs and can be induced by IL-1b (34, 36) . HA synthesis is enhanced in GD-OFs by several cytokines, including IFN-g (38) , leukoregulin (39), CD40 ligand (CD154) (40) , and IL-1b (37) . A recent study disclosed that IGF-I could also induce HA synthesis in GD-OFs (41) and could skew generation toward high-molecular mass HA in perimysial GD-OFs (42) . In contrast, one report found that the induction by IGF-I of HAS2 mRNA in GD-OFs occurred only in the presence of a MAPK inhibitor (43) . Forkhead transcription factors have a potentially important role in regulating HA synthesis in these cells (44) .
Fat expansion frequently contributes to tissue remodeling in TAO and in some cases predominates in the development of proptosis (45) . Adipogenic potential of GD-OFs appears to underlie, at least in part, expansion of orbital tissue (46, 47) . These cells express peroxisome proliferator-activated receptor g (PPARg). When this receptor is activated, GD-OFs undergo differentiation into triglyceride-accumulating adipocytes (14, 46, 48) . Once differentiated, they express elevated levels of TSHR compared with undifferentiated cells (19) . It is currently thought that the combination of HA accumulation and adipogenic activity of GD-OF accounts for expansion of orbital connective tissue in TAO.
GD-OFs as Sources of Proinflammatory Cytokines
GD-OFs generate several cytokines that appear to play roles in TAO (1) . Many of these have been detected in affected orbital tissues or were found to be generated in activated GD-OFs in vitro. Cytokines detected in situ in TAO include TNF-a, IL-1a, IL-6, IL-8, IL-10, IL-12, IL-13, and IFN-g (49, 50) . Several of these are more highly expressed in active vs stable disease and include IL-1b, IL-6, IL-8, and IL-10 (50). That study also suggested a predominance of T helper (Th)1 cytokines in active TAO. Both IFN-g and TNF-a induce B cell activating factor in GD-OFs, an induction that appears to be more robust than in cells cultivated from healthy orbital tissues (51) . IL-1b induces both IL-16 and RANTES in GD-OFs and in so doing enhances the release of T cell migration-promoting activity (52) . The same actions are true for IGF-I and immunoglobulins from patients with GD (53, 54) . Additionally, IL-1b, IL-1a, IL-6, IL-1 receptor antagonist, and TGF-b are inducible in GD-OFs (55-57).
GD-OFs Express Molecular Machinery to Generate Arachidonic Acid Derivatives
The repertoire of proinflammatory genes expressed and highly inducible in GD-OFs includes those encoding biosynthetic enzymes for generating prostanoids and eicosanoids. In the cytokine-activated state, GD-OFs produce substantial levels of prostaglandin E 2 (PGE 2 ) (58) and 15-hydroxyeicosatetraenoic acid (59) . This results from active arachidonic acid generation and from the robust induction of several enzymes. CD40 ligand, leukoregulin, and IL-1b induce high levels of prostaglandin endoperoxide H synthase-2 (PGHS-2), the inflammatory cyclooxygenase (15, 40) , and glutathione-dependent PGE 2 synthase (60). Both specific and nonselective cyclooxygenase inhibitors and glucocorticoids attenuate the cytokine-dependent PGE 2 synthesis in GD-OFs. A recent report suggests that sphingosine-1-phosphate (S1P) pathways are involved in mediating the induction of PGHS-2 in GD-OFs (61) . That report suggests that the five S1P receptor subtypes are differentially expressed in tissues from patients with TAO compared with healthy orbital tissues. Levels of S1P 1 , S1P 2 , and S1P 3 receptors are elevated in TAO whereas those for S1P 4 and S1P 5 are higher in healthy tissues. PGE 2 can drive the T cell skew toward a Th2 phenotype and can enhance immunoglobulin synthesis by B cells (62, 63) . When engaged with the Th2 cytokine, IL-4, these cells express 15-lipoxygenase-1 (59) .
Understanding the heterogeneity of OFs in TAO
GD-OFs are considerably more diverse with regard to their cellular phenotypes in vitro than are fibroblast cultures from healthy orbits and those from other tissues such as skin. Among the first cell markers used to distinguish fibroblast populations was the surface molecule CD90 [thymocyte antigen 1 (Thy-1)], the natural ligand for which remains uncertain but whose role in lymphocyte and thymocyte behavior appears vast (64, 65 T cells (80) . In general, cytokines such as INF-g and IL-12 (Th1) inhibit fibrocyte differentiation from monocytes, whereas Th2 cytokines, such as IL-4 and IL-13, enhance that process (81) . They participate in the fibrosis associated with several disease processes, including experimental bleomycin-induced lung fibrosis (76) . Much of what we currently understand about fibrocyte biology comes from studies of lung fibrosis in mouse models (82) . These models are currently being used to identify strategies for minimizing the morbidity associated with fibrocyte-directed fibrosis (83) (84) (85) . Fibrocytes exhibit remarkable developmental plasticity and can differentiate into multiple cell types, depending on the intracellular signaling pathways that become activated. These events, in turn, result from extracellular molecular cues coming from their cellular neighborhood. Fibrocytes undergo adipogenesis when exposed to PPARg agonists (86) . In contrast, TGF-b and endothelin 1 drive differentiation toward the myofibroblast phenotype while inhibiting adipogenesis. It is the myofibroblast phenotype, particularly the expression of smooth muscle actin, which conveys the contractile qualities of wound healing associated with fibrocytes. PPARg activation disrupts the stress-activated protein kinase/Jun N-terminal kinase signaling initiated by TGFb. Thus, the molecular niche surrounding fibrocytes in the tissues where they infiltrate critically determines their differentiation pathway.
Fibrocytes have been implicated in several disease processes such as those associated with idiopathic pulmonary fibrosis (87) . The abundance of CD45 2 collagen I + fibrocytes was found to be elevated in the blood of patients with stable idiopathic pulmonary fibrosis (87) . Levels were further increased, up to 10-fold, above those found in stable disease during acute exacerbations. Other comparators, such as patients with adult respiratory distress syndrome, were found to have normal fibrocyte levels (87) . Survival of patients with more abundant fibrocytes was considerably shorter than that of individuals with lower levels, suggesting that relative fibrocyte frequency may have predictive value for clinical outcome. Nephrogenic systemic fibrosis occurs in individuals manifesting dermal hardening and thickening associated with renal insufficiency (88) . Typically, the affected dermal tissues are infiltrated with fibrocytes, evidence of mucin deposition and thickened collagen bundles. Systemic sclerosis can also be associated with increased levels of fibrocytes (89) .
Identifying Fibrocytes as Discrete, Putative Progenitors of a GD-OF Subset in TAO
Fibrocytes have been implicated in the development of multiple ocular-related diseases (90) . Among these, diabetic retinopathy development may be mediated at least in part by fibrocytes (91) . In that process, fibrovascular membrane formation may result from their activities. Bone marrow-derived cells contributing to the myofibroblast population in corneal wounds (92) exhibit features suggestive of their derivation from fibrocytes. In GD, they have been identified as orbit-infiltrating cells (71) . Circulating CD34 + fibrocytes become considerably more abundant in patients with GD than in healthy individuals (Fig. 1) . Furthermore, it appeared that patients with severe, active TAO exhibited among the highest levels of circulating fibrocytes. CD34
+ cells have been identified in situ in deep TAO orbital fat. A subpopulation of GD-OFs cultivated from those tissues display CD34 (Fig. 2) 
Fibrocytes Promiscuously Express Autoantigens
Fibrocytes exhibit a characteristic repertoire of gene expression that includes proteins identified as autoantigens in endocrine autoimmune diseases. They express islet antigen 2 and islet cell autoantigen 69, two selfantigens associated with type I diabetes mellitus (101) . Relevant to GD, fibrocytes express not only TSHR but also thyroglobulin (Tg), thyroperoxidase, and sodium iodide symporter (93, 102) , proteins initially thought to be restricted to the thyroid gland (93) . Their expression is dependent on the noncanonical transcription factor autoimmune regulator protein (AIRE) (Fig. 4) . Knocking down AIRE expression with targeting small interfering RNA (siRNA) depresses thyroid protein levels (102) . Moreover, fibrocytes from an individual with autoimmune polyendocrinopathy-candidiasisectodermal dystrophy/dysplasia type 1 syndrome, who harbored a loss-offunction AIRE mutation, were found to express significantly lower levels of these proteins than cells from an unaffected first-degree relative. Preliminary studies suggest that the expression of islet antigen 2 and islet cell autoantigen 69 in fibrocytes may be independent of AIRE (101) .
In contrast to the relatively high levels of thyroid proteins and AIRE expression in fibrocytes, those proteins are either undetectable in GD-OFs or the levels are extremely low (Fig. 5) (111, 112) . ROBOs are transmembrane receptors distributed widely within the central nervous system and in other tissues as well. Slit2 has been shown to also play roles outside the nervous system, such as regulating the inflammatory response (113) . It inhibits monocyte chemotaxis through actions mediated by ROBO1 (114) and modulates immune reactivity. Recent evidence suggests that Slit2 can attenuate the differentiation of monocytes into fibrocytes (115) . Those pivotal studies indicated that Slit2 generated by fibroblasts surrounding injured lung tissues helps determine the magnitude of fibrosis. Thus, it may represent an Given the effects of Slit2 on fibrocyte differentiation, examination of its potential impact on the expression of immune-and thyroid-related genes in these cells was undertaken. Slit2 was found to be expressed by GD-OFs, activity that localized specifically to CD34 2 OFs (103). The protein is highly inducible by TSH and M22, a monoclonal TSI (116), through both transcriptional and posttranscriptional mechanisms. Medium conditioned by CD34 2 OFs substantially reduces levels of AIRE, Tg, TSHR, and MHC-II when incubated with fibrocytes. Levels of expression can be restored by specifically adsorbing out Slit2 (Fig. 6 ) (103). Recombinant human Slit2 mimics the actions of the CD34 2 OF conditioned medium and does so by downregulating the transcription of genes encoding AIRE and Tg (103) . Thus, Slit2 appears to represent at least one factor that is expressed and released by CD34 2 OFs and that may modulate the proinflammatory phenotype of orbit-infiltrating fibrocytes in TAO (Fig. 7) .
Fibrocytes and Their Putative Derivative CD34 + OFs as Potential Therapeutic Targets in TAO
Given their potential role in the pathogenesis of TAO, fibrocytes might be targeted as a therapeutic strategy. This approach would in theory aim at interrupting both the inflammatory responses and tissue remodeling. The underlying conceptual premise of targeting fibrocytes hinges on their putative regulation of the quality and duration of the tissue disruption and repair. They express several antigens specific to thyroid autoimmunity (71, 93, 102) , efficiently present antigens to T cells, display critical coactivational molecules such as CD80 and CD86 (78, 117) , and generate an extensive array of cytokines (97, 118, 119) . Thus, they could be considered a "switchboard" for the immune responses occurring within the TAO orbit. Recognizing their generation of extracellular matrix molecules, including glycosaminoglycans, fibronectin, and collagen, strongly suggests that modifying these biosynthetic activities could mitigate several adverse consequences of the disease. It is therefore possible that reducing their abundance or behavior, either in circulation or while inhabiting orbital tissue, could alter the disease course and outcome. The endgame would be to reduce disease morbidity and the need for rehabilitative ocular surgeries.
Several factors have been shown to retard fibrocyte differentiation besides Slit2. These factors could prove useful as treatments for TAO. Among them, serum amyloid p (SAP) has been characterized as a fibrocyte-inhibitory agent (120) , the actions of which are mediated through Fcg receptors that are distinct from those blocking neutrophil adhesion (121) . A role for SAP in vivo in modulating tissue reactivity was demonstrated in SAP knockout mice (122) . These mice exhibit persistent inflammation and fibrosis following administration of the lung fibrosis-promoting agent, bleomycin, when compared with wild-type controls. Very recently, IL-4 was shown to markedly enhance fibrocyte differentiation, an activity that could be inhibited by the store-operated Ca 2+ entry channel blocker SKF-96365 (123) . SAP could block this enhancement by IL-4, apparently utilizing a mechanism mediated through the Ca 2+ channel. Inhibitors of C-type lectin dendritic cellspecific intracellular adhesion molecule 3-grabbing nonintegrin might also be effective in attenuating fibrocyte differentiation (124) . A recent report from Ko et al. (125) provided evidence that blocking the synthesis of S1P and its receptor in GD-OFs could attenuate collagen, fibronectin, and smooth muscle actin synthesis/expression as well as the induction of several metalloproteases by TGFb. Although not localizing the effects to the CD34 + OF subpopulation, these findings suggest that inhibiting this pathway could be related to the activities in fibrocytederived cells. Should this prove to be the case, the actions of this agent could prove cell type specific. Alternatively, fibrocyte activity could be attenuated by interrupting TSHR/IGF-IR postreceptor signaling. Several inhibitory small molecules targeting TSHR have exhibited activity both in vitro and in small animal models (126) (127) (128) (129) . Monoclonal antibodies that antagonize TSHR activity have also been described (130, 131, 132) . It remains possible that one or more of these or similar agents will emerge as well tolerated and effective in treating TAO. Because these molecules should also attenuate the actions of pathogenic TSIs on the thyroid gland and therefore potentially correct hyperthyroidism, they might represent "all-in-one" treatment options for GD. Fibrocyte activity appears to be susceptible to downregulation by specific inhibition of IGF-IR. We have found that immunoglobulins from patients with GD and IGF-I can induce the expression of RANTES and IL-16 in GD-OFs (53, 54) . Those and subsequent studies disclosed overexpression of IGF-IR in GD-OFs and T cells and increased abundance of IGF-IR + B cells in GD (54, 133, 134) . Furthermore, Tsui et al. (135) reported that IGF-IR and TSHR form physical and functional protein complexes and that inhibition of IGF-IR activity can block signaling downstream from TSHR. These observations represent an important rationale for the use of teprotumumab in treating active TAO. Teprotumumab is a fully human IgG1 that inhibits IGF-IR (136) . It has proven safe and effective in a recently completed placebo-controlled clinical trial in moderate to severe, active TAO (137) . Cytokine induction by TSIs and TSH in fibrocytes and GD-OFs can be reduced substantially by teprotumumab in vitro (100).
Conclusions
Fibrocytes and derivative CD34 + OFs appear to be actively involved in the pathogenesis of TAO as a consequence of their presence in the circulation and orbit. Their repertoire of expressed genes and cellular responses to pathogenic signals insinuates them in the development of this disease. Within tissues, they interact with residential CD34 2 OFs that condition their behavior. As dominant effectors of pathogenic processes, they appear to possess potential as therapeutic targets. Many aspects of fibrocyte involvement in TAO remain uncertain. Among the most important is whether their relative abundance when compared with CD34 2 OFs changes as disease activity diminishes, in more severe disease, or in response to therapy. Another relates to whether differences in the phenotype of fibrocytes from one individual to another might underlie the divergent clinical courses of TAO observed in patients. In any event, recognition of fibrocytes and their derivatives as components of orbital biology in health and disease should prove of great importance as we further clarify the process underlying TAO and strive to develop targeted therapies.
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